AAN:运动对轻度认知障碍者有益,吃药不管用

2018-01-03 许菁 中国循环杂志

近期,美国神经病学学会(AAN)更新指南,指出经常运动锻炼可改善轻度认知障碍患者的认知功能。


近期,美国神经病学学会(AAN)更新指南,指出经常运动锻炼可改善轻度认知障碍患者的认知功能。
 
此外,新指南并不肯定认知训练可以改善认知,而且并不认可药物治疗轻度认知障碍,因为没有高质量的证据支持药物治疗可减轻轻度认知障碍的症状。 
 
相关数据显示,轻度认知障碍的患病率随着年龄的增长而增加,年龄在60~64岁人群中患病率为6.7%,65~69岁为8.4%,70~74岁为10.1%,75~79岁为14.8%,80~84岁为25.2%。
 
数据还表明,年龄在65岁以上的轻度认知障碍患者随访2年,痴呆发生率为14.9%。
 
该指南建议轻度认知障碍患者应定期锻炼。长达6个月的研究表明每周两次的运动训练可以改善记忆力。
 
FDA目前还没有批准用于治疗认知障碍患者的药物,目前还没有高质量的长期研究表明药物或饮食的改变可以改善轻度认知障碍患者的认知功能。
 
原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=275632, encodeId=1e232e5632ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 05 08:09:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446446, encodeId=b1be1446446aa, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Fri Jan 05 07:25:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275299, encodeId=49a42e5299ef, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jan 04 07:46:34 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275103, encodeId=6a4a2e510315, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 03 18:20:36 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-05 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=275632, encodeId=1e232e5632ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 05 08:09:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446446, encodeId=b1be1446446aa, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Fri Jan 05 07:25:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275299, encodeId=49a42e5299ef, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jan 04 07:46:34 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275103, encodeId=6a4a2e510315, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 03 18:20:36 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-05 bluefate123
  3. [GetPortalCommentsPageByObjectIdResponse(id=275632, encodeId=1e232e5632ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 05 08:09:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446446, encodeId=b1be1446446aa, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Fri Jan 05 07:25:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275299, encodeId=49a42e5299ef, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jan 04 07:46:34 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275103, encodeId=6a4a2e510315, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 03 18:20:36 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-04 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=275632, encodeId=1e232e5632ba, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Jan 05 08:09:09 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446446, encodeId=b1be1446446aa, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Fri Jan 05 07:25:00 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275299, encodeId=49a42e5299ef, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Thu Jan 04 07:46:34 CST 2018, time=2018-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275103, encodeId=6a4a2e510315, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Jan 03 18:20:36 CST 2018, time=2018-01-03, status=1, ipAttribution=)]
    2018-01-03 wxl882001

    学习一下

    0

相关资讯

AAN 2014:Eteplirsen治疗杜氏肌营养不良安全有效

在某些杜氏肌营养不良症(DMD)患者中,Eteplirsen可以在超过2年的时间内安全地维持其对行走速度的有益作用,并且是首个能在这一时间段内稳定膈肌功能的药物。 Jerry R. Mendell博士 共同研究者兼研究资助者Edward M. Kaye博士深入报告了安全性和药代动力学数据:在这项小规模研究中,eteplirsen未引起明显的治疗相关不良事件。迄今尚无患者停止或

Neurology:两份贝尔麻痹临床实践指南的比较

摘要 贝尔麻痹——以苏格兰解剖学家查尔斯·贝尔命名,是一种常见的急性单神经病,又称特发性面神经麻痹或面神经炎。近两年内,美国神经病学会(AAN)和美国耳鼻喉-头颈外科学会(AAO-HNSF)均发布了各自的临床指南,旨在为贝尔麻痹患者提高护理质量和改善疾病预后。本篇述评主要比较了这两版指南中所涵盖范围及推荐规范的异同。 美国耳鼻喉-头颈外科学会近期发布了关于贝尔麻痹的临床

AAN 2014:疼痛感强度与DRD1基因突变有关

一项新的研究提供了有关基因促使疼痛感知的重要新见解。该研究结果发表于美国神经病学会(AAN)第66届年会。 该研究的主要研究人员,加利福尼亚欧文Proove 生物科学临床事务经理Tobore Onojighofia博士说,虽然这项研究对于慢性疼痛的治疗选择没有产生立竿见影的效果,但它将帮助医生了解一些患者的疼痛耐受性为什么较其他人更差。 他补充说,该研究也提供了对于疼痛的客观评估。“在这项研究